Preventive health exams increase colorectal cancer screening

Patients in a managed care organization who received periodic preventive health examinations  were more than three and a half times as likely to be screened for colorectal cancer as patients who didn’t  have physical checkups.  They also were more likely to be up-to-date with mammograms and tests for prostate cancer.

Dr. Joshua J. Fenton led a team of researchers who reviewed health records for almost 65,000 members of a managed care health plan in Washington State.  Plan enrollees were aged 52 to 78 years old and were eligible for colorectal cancer screening.  More than half received a preventive health screening between 2002 and 2003.

Colorectal cancer screenings included fecal occult blood testing, sigmoidoscopy, colonoscopy, or barium enema

Writing in the Archives of Internal Medicine the team concluded:

Among managed care enrollees eligible for cancer screening, preventive health screening (PHE) receipt is associated with completion of colorectal, breast, and prostate cancer testing. In similar populations, the PHE may serve as a clinically important forum for the promotion of evidence-based colorectal cancer and breast cancer screening and of screening with relatively less empirical support, such as prostate cancer screening.

SOURCE:  Fenton et.al., Archives of Internal Medicine, Volume 167, No. 6, pp. 580-585, March 26, 2007.

Posted by Kate Murphy on April 22nd, 2007
Posted in: Research & Treatment News | No Comments »

Most patients on cetuximab will have lowered magnesium levels

Almost all patients who are receiving the EGFR inhibitor cetuximab (Erbitux) will have decreasing levels of magnesium (hypomagnesemia). 

To study this side effect, Belgian researchers measured magnesium levels in the urine and blood of 98 patients receiving EGFR treatments, either as a single drug or in combination with chemotherapy.  97% of them had magnesium levels decrease during treatment.  Controls on only chemotherapy did not have a similar side effect.

Urine testing and a special IV magnesium load test revealed that the kidneys were not reabsorbing magnesium and returning it to the bloodstream.

Led by Prof. Sabine Tejbar, M.D., the team concluded:

EGFR-inhibiting antibodies compromised the renal magnesium retention capacity, leading to hypomagnesemia in most patients. Future studies should address the effects of exposure and target affinity. Our study suggests a pivotal role of the EGFR-signalling pathway in regulating magnesium homoeostasis.

SOURCE:  Tejbar et. al. Lancet Oncology, early online publication April 17, 2007.

Posted by Kate Murphy on April 21st, 2007
Posted in: Research & Treatment News | No Comments »

Washington Governor Chris Gregoire Signs Colorectal Cancer Screening Bill

We were pleased to hear from C3 Advocate Anita Mitchell that Washington State Legislature passed HR 1337, An ACT Relating to Insurance Coverage for Colorectal Cancer Early Detection.

HR 1337 will require insurance coverage for colorectal cancer screening for health plans issued or renewed on or after July 1, 2008. Insurance coverage will be provided for individuals who are at least 50 years of age or for those individuals who are considered to be at high risk for colorectal cancer.

We would like to thank the Washington State Legislature and Governor Gregoire for making strides in the right direction to combat this horrible disease.

Click here to read a copy of this bill.

Click here to see where your State ranks in the fight against colorectal cancer.

Governor Gregoire, C3 Advocate Anita Mitchell and her children at the bill signing.

Posted by Joe Arite on April 17th, 2007
Posted in: Policy & Advocacy News | No Comments »

Oral glutamine reduces oxaliplatin neuropathy in pilot study

While oxaliplatin is effective in colorectal cancer to increase survival time and prevent recurrence, it can cause serious peripheral neuropathy.  Tingling, numbness, and pain in hands and feet can interfere with daily functioning and impair quality of life.  If it becomes bad enough, doses of oxaliplatin must be reduced or discontinued entirely.

Researchers in Taiwan randomized 86 metastatic colorectal patients being treated with oxaliplatin to receive oral glutamine or not to see if the supplemental protein would reduce neuropathy.  Patients were receiving their first treatment for metastatic colon or rectal cancer.  Oxaliplatin was combined with leucovorin and bolus 5FU.

Although oxaliplatin does cause a short-term neuropathy in hands, feet, jaw, and larynx which can be triggered by exposure to cold, these symptoms usually get better within a few days of treatment and don’t interfere with further doses of chemotherapy.  So instead, the research team focused on long-term peripheral neuropathy in hands and feet which gets worse over time as the dose of oxaliplatin accumulates.

The patients in the glutamine group received 15 grams of levo-glutamine (Sympt-X® manufactured by Baxter Health Care Corporation) twice a day for seven days every two weeks, beginning on the day of the oxaliplatin infusion.  To avoid confusion, no patients had potentially protective infusions of calcium and magnesium.

Neurological symptoms and ability to accomplish fine motor activities of daily living such as buttoning buttons and opening jars were assessed at the beginning of therapy and after 2, 4, and 6 cycles of treatment.  In some cases more extensive electrophysiological neurological tests were carried out.

There were significantly fewer neurological symptoms in patients who received glutamine than in those who did not.

• After two treatment cycles, 16.7% of the glutamine group experienced grade 1-2 sensory neuropathy compared to 38.6% of the control group.
• After four cycles, 26.2% of the glutamine group had grade 1-2 neuropathy compared to 36.4% of controls.
• Grade 3-4 neuropathy after four cycles was 4.8% in the glutamine group and 18.2% in controls.  Grade 3 and 4 neuropathy is associated with pain and loss of normal function.
• Grade 3-4 neuropathy after six cycles was 11.9% versus 31.8% in controls.
• Acute, transient, cold-induced neuropathy was also significantly decreased by glutamine supplements — 33.3% versus 56.8%.
• Interference with activities of daily living was 16.7% with glutamine versus 40.9% of the control group.

However, electrophysiological tests, conducted on 14 members of the glutamine group and 14 controls, did not show a significantly objective difference.  The team wrote:

Although glutamine supplementation significantly reduced the incidence of “subjective” neuropathy in these patients, it did not exert a protective effect on the deterioration of electrophysiological tests.

Although patients in the glutamine group required fewer oxaliplatin dose reductions, there was no difference in treatment effectiveness.

• No patients in either group had their cancer get worse (progress) after three treatment cycles.
• After six treatment cycles, about twenty percent of each group had progressing cancer.
• About half of each group responded to treatment with tumor shrinkage.
• Median survival for the glutamine group was 17.3 months versus 18.6 months for controls, not a significant difference.

Overall, the research team, led by Wei-Shu Wang, concluded:

In summary, our data suggest that oral glutamine has a potential neuroprotective effect in MCRC patients treated with oxaliplatin, and may therefore improve the therapeutic index. Larger placebo-controlled, randomized studies are needed to confirm the application of glutamine as a protective agent against oxaliplatin-induced neuropathy.

Glutamine is the most abundant protein in blood and in skeletal muscles.  It is available as a nutritional supplement and is sometimes used during exercise and body building to improve performance.  It can be reduced in the muscles during stress, cancer, and chemotherapy.  Previously it has protected breast cancer patients receiving high doses of Taxol from neuropathy.

SOURCE:  Wang et. al. The Oncologist, Vol. 12, No. 3, 312-319, March 2007

WHAT THIS MEANS FOR PATIENTS

Posted by Kate Murphy on April 12th, 2007
Posted in: Research & Treatment News | 2 Comments »

Colon cancer survivor Leroy Sievers on NPR Talk of the Nation Monday

Leroy Sievers, who is living with metastatic colon cancer, is featured on National Public Radio’s call-in program Talk of the Nation, Monday, April 16th.  Live shows are carried by NPR stations at 2 p.m. and 3 p.m. Eastern time.  An audio webcast will be available on the Talk of the Nation site about  6 p.m. that day.

The show will be broadcast from Washington D.C. before a live audience.  People who want to be part of the audience should contact NPR at talk@npr.org.

Sievers writes an insightful daily blog  for NPR — My Cancer — where he chronicles his life dealing with colon cancer that has spread to his brain. 

Talking about the language of cancer, he writes,

Maybe the best thing to say is that we all just “deal with it.” Some days that involves fighting; other days, coping. Some days we don’t win, some days it’s a struggle to do the smallest thing and other days the battle swings our way. We all just deal with it in our own ways and do the best we can on any given day.

Sievers has won 12 national news Emmys and two Peabody awards.  He worked for ABC News Nightline for 14 years, four years as executive producers.  As a correspondent he covered more than a dozen wars, accompanying Ted Koppel during the invasion of Iraq.

His blog has many followers, both cancer patients and family members, who write often to comment on what he says each day.

Posted by Kate Murphy on April 12th, 2007
Posted in: Research & Treatment News | 2 Comments »